Compare CWST & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWST | TGTX |
|---|---|---|
| Founded | 1975 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.5B |
| IPO Year | 1997 | 1995 |
| Metric | CWST | TGTX |
|---|---|---|
| Price | $94.53 | $31.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $119.50 | $54.75 |
| AVG Volume (30 Days) | 542.6K | ★ 1.9M |
| Earning Date | 10-30-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 102.54 | N/A |
| EPS | 0.24 | ★ 2.78 |
| Revenue | ★ $1,795,272,000.00 | $531,898,000.00 |
| Revenue This Year | $20.34 | $82.31 |
| Revenue Next Year | $7.68 | $49.05 |
| P/E Ratio | $396.29 | ★ $11.35 |
| Revenue Growth | 20.54 | ★ 100.88 |
| 52 Week Low | $82.22 | $25.28 |
| 52 Week High | $121.24 | $46.48 |
| Indicator | CWST | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.51 | 46.02 |
| Support Level | $94.75 | $30.54 |
| Resistance Level | $97.21 | $33.79 |
| Average True Range (ATR) | 2.34 | 1.08 |
| MACD | 0.31 | 0.05 |
| Stochastic Oscillator | 69.40 | 37.69 |
Casella Waste Systems Inc is a solid waste removal company, providing resource management services to residential, commercial, municipal, and industrial customers. The company's reportable segments on Geographical basis include Eastern, Western and Mid-Atlantic regions through the Resource solution segment. It generates maximum revenue from the Western region segment. The company's services include Recycling, Collection, Organics, Energy, Landfills, Special Waste as well as Professional Services.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.